NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Optieum Biotechnologies

Optieum Biotechnologies

Private
JapanHealthcare & Life Scienceshttps://optieumbio.com/

Last Round

Grant

Mar 18, 2025

Total Funding Raised

$11.09M

Company Overview

Optieum Biotechnologies is a biotechnology company that develops antibody-based therapies intended to treat cancer and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapycell therapysolid tumor therapyCAR discovery platformplatform biotechimmunotherapyglioblastoma therapyscFv optimizationantibody-based therapydrug discoveryCAR-NK cell therapyautoimmune disease therapypreclinical biotechCDMO partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Optieum Biotechnologies Comparables

Compare Optieum Biotechnologies with similar companies based on industry and business-model similarity.

Optieum Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Optieum Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 18, 2025
Series AJan 14, 2025
GrantJan 27, 2022
SeedSep 30, 2021

Key People

Founding team and executive leadership

Shun Nishioka

Chief Executive Officer

Executive Team

Mikio C.

CFO

Executive Team

Optieum Biotechnologies Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 5, 2025

    Monthly visitors grew 461% MoM, reaching 3.3K.

  • Mar 18, 2025

    $39M grant from Japan Agency for Medical Research and Development.

Optieum Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Optieum Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Optieum Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersJapan
Employee Range14
Year Founded2020
Last FundingMar 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.